Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Biotechnology

Healthcare
$1.43 -2.40%

-$0.04 today

Market cap
$82.18M
Beta
3.23
P/E (TTM)
-2.2
EPS (TTM)
-$0.75
52W Low $1.62High $4.94

Volume 0.60M

Average 1.31M

Returns on capital

Black Diamond Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

19.9%

avg -10.9%

ROIC

15.2%

avg -39.8%

ROA

15.6%

avg -35.5%

Analysis

ROE is currently the strongest return metric at 19.9% versus its period average of -10.9%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Mark A. Velleca

Chief Executive Officer, President & ChairmanUSD 1.04M62600.00K1.05%

Sergey Yurasov

Chief Medical OfficerUSD 760.75K57250.00K0.44%

Brent Hatzis-Schoch

Chief Operating Officer & General CounselUSD 741.22K61250.00K0.44%

Elizabeth Buck

Co-Founder & Chief Scientific OfficerUSD 340.47K51250.00K0.44%

Melanie Morrison

Chief Development Officer—51——

Erika Jones

Principal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller—41200.00K0.35%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 21, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
+4.4% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Forward estimates point to Revenue at +4.4% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Black Diamond Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about BDTX's management, answered from reported figures.

Who manages BDTX?

Black Diamond Therapeutics, Inc. (BDTX) lists 6 active executives. The top listed executive is Elizabeth Buck, Co-Founder & Chief Scientific Officer.

Are BDTX insiders buying or selling?

Recent insider activity shows net buying of $47.09M.